November 21st 2024
The CDMO's California facility welcomes new production suites, a revamp of its development labs, and more.
November 14th 2024
The 50,000 square-foot plant is expected to augment the compounding and fulfillment experience for telehealth companies.
November 7th 2024
Tips for pharmacies with the reimbursement blues.
November 6th 2024
Digital transformation initiatives are often complex endeavors that can significantly impact the way organizations operate.
October 29th 2024
Are SDOHs associated with Medicare, Medicaid, and private insurer spending?
Express Scripts Drug Trend report: spending increase held to 3.8% in 2016
'Rebates do not raise drug prices, drug makers do,' says the PBM
US Drug Pricing Debate: Finding some dearly needed real solutions
A conversation with Mark Sell, MD Logistics
Pharma execs meet with President Trump; job growth on the table
Trump suggests a ‘streamlined’ FDA will accelerate industry growth
Supply chain is gobbling up more of pharmaceutical expenditures in the US
Brand manufacturers retain 47% of net expenditures for drugs
M&A up and down the pharma value chain
Thumbs up for J&J-Actelion; thumbs down for Aetna-Humana; Walgreens, McKesson actions
EY Firepower report: Big Pharma well-positioned for 2017 M&A activity
Watch for Washington tax policy reform to affect 2017 business
Elapsed time from discovery to launch remains ‘stubbornly long,’ says QuintilesIMS study
Shorter elapsed time in recent years shows encouraging improvement
Oops! ... FDA drug approvals slump badly in 2016
Only 20 new molecular entities passed muster this year, less than half of 2015’s total
Medical associations, policy groups organize to fight counterfeit drugs and rogue online pharmacies
New consumer-education campaign led by Alliance for Safe Online Pharmacies
Senators wrap up Turing-Valeant hearings on price gouging
A preamble for a next round of legislating drug pricing?
Walgreens-Rite Aid will sell 865 Rite Aid stores to Fred’s Pharmacy
Action is expected to meet FTC objections to the merged chains announced in 2015
CMS withdraws its proposed alternative payment models in pharmaceutical reimbursement
Back to square one in addressing high-cost-drug spending
More drug-pricing trouble: generic manufacturers are accused of price collusion
Connecticut leads 20 states suing an alleged ring led by Heritage Pharma
Lilly counters rising criticism of insulin drug prices with a PBM-driven, open-access discount
First branded-product discount program from Blink Health
2016 HDA Factbook: primary distributors handle 93.8% of US drug distribution
Higher productivity and more complexity; but slow takeup of traceability requirements
QuintilesIMS drug spending outlook: $1.5 trillion in 2021, up 33%
Growth rates will moderate in the US and world
Here comes the 21st Century Cures Act
Bills passes House with broad bipartisan support; Senate approval likely
PCMA survey: consumers blame pharma for high prices and high OOP
A counterargument to the belief that out-of-pocket expenses originate with insurers or PBMs
Patheon picks up a Roche facility in South Carolina
Sale comes with multi-year supply agreement
Catalent adds to softgel capacity with proposed acquisition of Accucaps
Two Canadian Accucaps facilities join global network of 11 Catalent RP Scherer Softgel locations
Life sciences is a good recycler of real estate
Allergan’s big commitment to NJ; U. of Michigan converts pharma facilities to healthcare and education
Former Valeant and Philidor executives arrested by DoJ
Upcoming trial could explore the intricacies of ‘alternative fulfillment’ via specialty pharmacies
EzriRx seeks to consolidate pharma purchases for independent pharmacies
An Amazon-like model for creating an open market for wholesalers to reach customers
A conversation with Jim Mullen, Patheon
Turning up the heat on PBM’s role in drug pricing
Will employer benefit plans lose their enthusiasm for PBMs?
AmerisourceBergen quarterly results: what industry downturn?
Revenues and earnings were up for the year; stock jumps 8.8% in the day
Winter is coming sooner for Big Three wholesalers
McKesson disappoints on Q2 earnings call; stock drops 23%. Update: Cardinal reports more revenue, less profit
GPhA: generics saved $227 billion in drug costs in 2015
Price growth is less than branded growth, but higher than inflation
More trouble for Mylan over EpiPen pricing and rebates [updated]
Company may have erroneously been operating under a generic classification